Announcement on Key Operating Data for the First Half of 2026
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
The report includes revenue and cost figures segmented by industry, region, and sales model, providing insights into the company's operational performance.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang CONBA Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang CONBA Pharmaceutical
- Announcement on Progress in Public Listing for Transfer of 100% Equity in Dongyang Kang'enbei Printing and Packaging Co., Ltd.
- Indicative Announcement on the Restricted Exercise Period under the 2022 Stock Option Incentive Plan
- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for New Indication of Shexiang Tongxin Dropping Pills by Subsidiary
- Announcement on the Subsidiary's Rivaroxaban Tablets Obtaining Supplementary Approval for Additional Specifications and Other Matters
- Announcement on Inclusion of Products of the Company and Its Subsidiaries in the "National Essential Medicines List (2026 Edition)"
Later from Zhejiang CONBA Pharmaceutical
- Announcement on Completion of Filing of Industrial and Commercial Registration Changes for the Transfer of 100% Equity Interest in Dongyang CONBA through Public Listing
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Resolutions of the 21st (Extraordinary) Meeting of the 11th Board of Directors
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Receipt of Drug Registration Certificate for Dapoxetine Hydrochloride Tablets by Subsidiary
- (600572)"Zhejiang CONBA Pharmaceutical Co., Ltd."Announcement on Self-exercise Results in Q3 2026 under the Stock Option Incentive Plan and Share Changes
Follow Zhejiang CONBA Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang CONBA Pharmaceutical